This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content is only relevant to HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

For HCPs in Northern Ireland please contact Customer Services on 0800 854 430 for further information


Verorab pack shot

Verorab is an inactivated vaccine indicated for pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) against rabies in all age groups.1,2

Now with 1 week PrEP regimens - see usage table below for details.

Before you prescribe or administer this vaccine please refer to the Prescribing Information.

Prescribing Information - GB

Prescribing Information - NI


Why help protect your patients with Verorab?

  • Rabies is an acute viral infection causing inflammation of the spinal cord and the brain.3
  • The incubation period of the disease is usually 2-3 months but can be anything from a week to 1 year. 3
  • In developing countries, where it is most often transmitted by dogs, rabies is still considered a major public health concern. 3
  • Transmitted through the saliva of an infected mammal, usually via a bite, scratch or lick. 4

Rabies kills almost 60,000 people every year – which is roughly 1 person every 9 minutes 5

Travel related rabies deaths are preventable through timely pre- and post-exposure measures.6,7


View the Infographic

Watch the Video

Download the Map


View the Infographic

Watch the Video

Download the Map



VERORAB® is indicated for pre-exposure and post-exposure prophylaxis of rabies in all age groups. Verorab should be used according to official recommendations.
PresentationVERORAB® is available as a powder containing the active substance to be reconstituted with solvent. The vaccine should be administered immediately after reconstitution using the intramuscular or within 6 hours using the alternate intradermal route.
PosologyThe recommended dose is 0.5 mL of reconstituted vaccine intramuscularly (IM), or 0.1 mL of reconstituted vaccine intradermally (ID) for pre-exposure or post-exposure usage.

Pre-exposure prophylaxis (PrEP) (SmPC):

  • Conventional regimen: Intramuscular 0.5 mL - 3 doses on Days 0, 7 and 21 or 28 days
  • 1-Week Regimen: Intramuscular 0.5 mL - 2 doses on Days 0 and 7
  • 1-Week Regimen: Intradermal 0.1 mL - 2 doses on Day 0, and 2 doses on Day 7

Immunocompromised individuals: A 3-dose regimen should be used and serology testing for neutralising antibodies should be performed 2-4 weeks after vaccination to assess the need for additional doses.

Post-exposure prophylaxis (PEP) (SmPC):

Post-exposure prophylaxis should be initiated as soon as possible after suspected exposure to rabies.

In all cases, proper wound care (careful washing of all bites and scratches with soap or detergent and copious amounts of water and/or virucidal agents) must be performed immediately or as soon as possible after exposure.

It must be performed before administration of vaccine or rabies immunoglobulins, when they are indicated.

In previously immunised individuals: 2 further doses on day 0 and day 3

In previously non-immunised individuals: The first injection of rabies vaccine (day 0) should be given as soon as possible and can be followed by a further 4 doses on days 3, 7, 14 and 28

Immunocompromised individuals: A complete vaccine regimen should be administered post-exposure. Rabies immunoglobulin should be administered concomitantly as per local official recommendations.

There are additional post-exposure prophylaxis options.

Further DosesFor those at continued risk booster doses should be given in line with official recommendations.
Age RangeNo lower or upper age limit listed.
Ways to order

You can order Sanofi Vaccines in two ways: online at VAXISHOP or through our call centre. Read more about ordering vaccines

CALL 0800 854 430


  1. Verorab GB Summary of Product Characteristics May 2024
  2. Verorab NI Summary of Product Characteristics May 2024
  3. WHO Rabies Factsheet. Available at: Accessed May 2024
  4. Travel Health Pro. Rabies. Available at: Accessed May 2024
  5. WHO. Zero by 30: the global strategic plan to end human deaths from dog-mediated rabies by 2030.
    Available at: Accessed May 2024
  6. Parize P, et al. Vaccine. 2021; 9(4): 309
  7. Kessels JA, et al. Bull World Health Organ. 2017; 95(3): 210

MAT-XU-2400750 (v2.0) | May 2024